The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 14 December 2004, www.theannals.com, DOI 10.1345/aph.1E163.
 The Annals of Pharmacotherapy: Vol. 39, No. 2, pp. 237-242. DOI 10.1345/aph.1E163
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breekveldt-Postma, N. S
Right arrow Articles by Herings, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breekveldt-Postma, N. S
Right arrow Articles by Herings, R. M.

HYPERTENSION

Persistence with Antihypertensives Related to Formulation: The Case of Nifedipine

Nancy S Breekveldt-Postma, PhD

Research Scientist, PHARMO Institute, Utrecht, Netherlands

Ron MC Herings, PharmD PhD

Scientific Director, PHARMO Institute

Reprints: Dr. Breekveldt-Postma, PHARMO Institute, PO Box 85.222, 3508 AE Utrecht, Netherlands, fax 31 30 2345 568, pharmo{at}pharmo.nl

BACKGROUND: Controlled-release dosage forms may enhance persistence with therapy because of reduced dosing frequency and fewer adverse effects.

OBJECTIVE: To assess the differences in persistent use of nifedipine between once-daily nifedipine gastrointestinal therapeutic system (GITS) and twice-daily nifedipine retard formulations.

METHODS: Incident nifedipine users were selected from January 1992 to December 2001 from the PHARMO database, including drug-dispensing records and hospital records of more than one million subjects in the Netherlands. Patients with unaltered formulation and dosing frequency of nifedipine in the first year of follow-up with at least 2 prescriptions were included in the cohort. Persistence with different formulations was assessed using Cox's proportional hazard analyses. Covariates included in the analysis were, among others, hospitalizations and comedication for cardiovascular diseases.

RESULTS: In total, 5889 incident users of nifedipine were included. The median duration of the first treatment episode was 133 days for nifedipine retard and 262 days for nifedipine GITS. One-year persistence with nifedipine increased from 32% in patients using retard formulations to 44% in patients using nifedipine GITS. Multivariate analyses showed that patients using nifedipine GITS were 1.3 times (RR 1.33; 95% CI 1.22 to 1.46) more persistent than those using retard formulations of nifedipine. Persistent patients more often used other antihypertensive drugs and were more often hospitalized for cardiovascular diseases.

CONCLUSIONS: Patients using once-daily nifedipine GITS are more persistent with therapy than patients using twice-daily retard formulations.

Key Words: nifedipine, persistence

Published Online, December 14, 2004. www.theannals.com, DOI 10.1345/aph.1E163




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.